Dr. Reddy’s reports 37 percent jump in profit for 2nd quarter
October 23rd, 2010 - 5:59 pm ICT by IANSNew Delhi, Oct 23 (IANS) Pharmaceutical major Dr. Reddy’s Laboratories Saturday reported a net profit of Rs.2.9 billion ($64 million) for the quarter ended Sep 30, which adds up to a 32 percent increase over the like period of the previous year.
In a filing with stock exchanges, the company said its consolidated revenues registered a marginal year-on-year growth of 2 percent for the quarter under review at Rs.18.7 billion ($420 million) against Rs.18.4 billion ($412 million) in like period last year.
During the year, the company launched 41 new generic products, filed for 21 new product registrations and gave confidential information on 13 processes, facilities and related information to regulators globally.
According to the pharmaceutical major, revenues from global generics segment grew 8 percent at Rs.13.7 billion, while that for custom pharmaceutical services and active ingredients stood at Rs.4.6 billion.
- Infosys lowers guidance for fiscal 2013 (Lead) - Apr 13, 2012
- Wipro net flat in second quarter - Oct 31, 2011
- Wipro net up 14 percent in fourth quarter - Apr 27, 2011
- Wipro outlook cautious on flat growth (Lead) - Apr 25, 2012
- Infosys projects 21 percent revenue growth - Apr 13, 2012
- Chinese aviation industry profits shrink - May 08, 2012
- Infotech's revenues up by 30 percent - Apr 18, 2012
- Wipro's IT outlook remains flat on marginal growth (Lead) - Jan 20, 2012
- Mahindra Satyam's net profit up by six percent - Nov 10, 2011
- Infosys ups annual guidance again on double digit growth - Jan 13, 2011
- Wage hike dips Wipro net, projects flat growth - Jul 20, 2011
- No impact of uncertainty on IT business: Premji (Lead) - Jul 20, 2011
- Vodafone India quarterly revenue rises 8.9 percent - Jul 22, 2011
- Wipro net up 10 percent in second quarter - Oct 22, 2010
- Granules India's revenues rise 37 percent - Apr 24, 2012
Tags: active ingredients, confidential information, consolidated revenues, dr reddy, generic products, net profit, New Delhi, pharmaceutical services, previous year, product registrations, regulators, rs 2, segment, stock exchanges